On August 19, 2025, BiomX Inc. reported that the FDA placed a clinical hold on its Phase 2b study for drug candidate BX004 intended to treat Cystic Fibrosis, while patient enrollment in the U.S. is paused. However, the study continues in Europe as the nebulizer device used is CE marked.